3,430 Stryker Corporation $SYK Shares Sold by Liberty Capital Management Inc.

Liberty Capital Management Inc. lowered its stake in Stryker Corporation (NYSE:SYK) by 25.4% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 10,093 shares of the medical technology company’s stock after selling 3,430 shares during the period. Liberty Capital Management Inc.’s holdings in Stryker were worth $2,780,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of SYK. Alta Advisers Ltd lifted its holdings in Stryker by 86.8% during the 3rd quarter. Alta Advisers Ltd now owns 2,486 shares of the medical technology company’s stock worth $685,000 after purchasing an additional 1,155 shares during the last quarter. Principle Wealth Partners LLC boosted its stake in Stryker by 4.2% in the 3rd quarter. Principle Wealth Partners LLC now owns 2,446 shares of the medical technology company’s stock valued at $674,000 after purchasing an additional 98 shares during the period. Platform Technology Partners boosted its stake in Stryker by 5.3% in the 3rd quarter. Platform Technology Partners now owns 793 shares of the medical technology company’s stock valued at $218,000 after purchasing an additional 40 shares during the period. Schmidt P J Investment Management Inc. grew its holdings in Stryker by 1.7% in the 3rd quarter. Schmidt P J Investment Management Inc. now owns 23,222 shares of the medical technology company’s stock valued at $6,395,000 after buying an additional 390 shares in the last quarter. Finally, Capital Investment Services of America Inc. grew its holdings in Stryker by 0.7% in the 3rd quarter. Capital Investment Services of America Inc. now owns 77,122 shares of the medical technology company’s stock valued at $21,239,000 after buying an additional 535 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on SYK shares. Wells Fargo & Company dropped their target price on Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a report on Wednesday, September 9th. Argus set a $370.00 target price on shares of Stryker in a research report on Thursday, July 9th. Robert W. Baird decreased their price target on shares of Stryker from $385.00 to $334.00 in a research note on Friday, October 30th. Citizens Jmp lowered their price target on shares of Stryker from $400.00 to $390.00 and set a “market outperform” rating on the stock in a research report on Friday, October 30th. Finally, BTIG Research dropped their price objective on shares of Stryker from $316.00 to $304.00 and set a “buy” rating for the company in a research note on Friday, October 30th. Twenty-one research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $343.73.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 300,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the sale, the director owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Debra King sold 826 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 351,267 shares of company stock valued at $118,197,701 in the last ninety days. 4.60% of the stock is currently owned by company insiders.

Stryker Price Performance

Shares of NYSE SYK opened at $334.85 on Friday. The business has a fifty day moving average price of $292.31 and a two-hundred day moving average price of $323.76. The stock has a market capitalization of $127.47 billion, a PE ratio of 23.78, a P/E/G ratio of 2.33 and a beta of 0.78. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.18 and a quick ratio of 1.30. Stryker Corporation has a fifty-two week low of $267.00 and a fifty-two week high of $389.33.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.55 by ($0.03). Stryker had a return on equity of 23.74% and a net margin of 13.78%. The company had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.62 billion. During the same period last year, the company posted $3.19 earnings per share. The business’s revenue for the quarter was up 7.6% compared to the same quarter last year. As a group, equities analysts predict that Stryker Corporation will post 14.84 earnings per share for the current fiscal year.

Stryker Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.